rs1555185969
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_003482.4(KMT2D):c.14878C>T(p.Arg4960*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_003482.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Kabuki syndrome Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 547499). This premature translational stop signal has been observed in individual(s) with Kabuki syndrome (PMID: 21280141). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg4960*) in the KMT2D gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in KMT2D are known to be pathogenic (PMID: 22126750). -
Kabuki syndrome 1 Pathogenic:1
- -
Inborn genetic diseases Pathogenic:1
The c.14878C>T (p.R4960*) alteration, located in exon 48 (coding exon 48) of the KMT2D gene, consists of a C to T substitution at nucleotide position 14878. This changes the amino acid from an arginine (R) to a stop codon at amino acid position 4960. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. for KMT2D-related Kabuki syndrome; however, it is unlikely to be causative of KMT2D-related multiple congenital anomalies disorder. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been reported in multiple individuals with KMT2D-related Kabuki syndrome, including multiple cases of reported de novo occurrence (Paulussen, 2011; Banka, 2012; Aref-Eshghi, 2017; So, 2021; Levy, 2022). Based on the available evidence, this alteration is classified as pathogenic. -
KMT2D-related disorder Pathogenic:1
The KMT2D c.14878C>T variant is predicted to result in premature protein termination (p.Arg4960*). This variant has been reported as a recurring de novo variant in multiple individuals with Kabuki Syndrome (Paulussen et al. 2011. PubMed ID: 21280141; So et al. 2021. PubMed ID: 33314698; internal cases at PreventionGenetics). This variant has not been reported in a large population database, indicating this variant is rare. Nonsense variants in KMT2D are expected to be pathogenic. Given the evidence, we interpret this variant as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at